Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onvansertib - Cardiff Oncology

Next Previous
Search
Drug Profile

Onvansertib - Cardiff Oncology

Alternative Names: NMS-1286937; NMS-P937; Onvansertib-fumarate; PCM-075; PCM-075H

Latest Information Update: 13 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Cardiff Oncology
  • Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer
  • Phase I/II Triple negative breast cancer
  • Phase I Chronic myelomonocytic leukaemia
  • Preclinical Medulloblastoma; Ovarian cancer
  • No development reported Lung cancer; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 27 Feb 2025 Adverse event data from a phase II trial in Colorectal cancer released by Cardiff oncology
  • 03 Feb 2025 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT06736717)
  • 24 Dec 2024 Cardiff Oncology completes a phase-II clinical trials in Pancreatic cancer (Second-line therapy or greater, Combination therapy, Metastatic disease) in USA (PO) (NCT04752696)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top